Back to Journals » Blood and Lymphatic Cancer: Targets and Therapy

ESCI

Blood and Lymphatic Cancer: Targets and Therapy


        

ISSN: 1179-9889

Editor-in-Chief: Dr Wilson Gonsalves

An international, peer reviewed, open access journal focusing on blood and lymphatic cancer research, identification of therapeutic targets, and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for the cancer patient.

The journal welcomes submitted papers covering original research, basic science, clinical & epidemiological studies, reviews & evaluations, guidelines, expert opinion and commentary, case reports, and extended reports.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).

Indexed online:

Articles:

Latest articles:

- 5 records -

Review

Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review

Bender C, Maese L, Carter-Febres M, Verma A

Blood and Lymphatic Cancer: Targets and Therapy 2021, 11:25-40

Published Date: 19 April 2021

Review

BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma

Gupta VA, Ackley J, Kaufman JL, Boise LH

Blood and Lymphatic Cancer: Targets and Therapy 2021, 11:11-24

Published Date: 12 March 2021

Original Research

The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia – A Single Center Retrospective Study

Liu Q, Major B, Le-Rademacher J, Al-Kali AA, Alkhateeb H, Begna K, Elliott MA, Gangat N, Hogan WJ, Hook CC, Kaufmann SH, Pardanani A, Patnaik MS, Tefferi A, Wolanskyj-Spinner AP, Wei W, Litzow MR

Blood and Lymphatic Cancer: Targets and Therapy 2021, 11:1-9

Published Date: 22 January 2021

Review

Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy

Sigmund AM, Sahasrabudhe KD, Bhatnagar B

Blood and Lymphatic Cancer: Targets and Therapy 2020, 10:7-20

Published Date: 3 November 2020

Original Research

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy

Ujjani C, Mato A, Hill BT, Allan JN, Lansigan E, Jacobs R, Tuncer H, Pagel J, Brander D, Cheson B, Barr P, Roeker LE, Pu J, Shah NN, Goy A, Schuster SJ, Lamanna N, Sehgal A, Tam CS, Shadman M

Blood and Lymphatic Cancer: Targets and Therapy 2020, 10:1-5

Published Date: 24 August 2020

 

Read more articles